IL258577B - 2,4-dihydroxy-nicotinamides as apj agonists - Google Patents
2,4-dihydroxy-nicotinamides as apj agonistsInfo
- Publication number
- IL258577B IL258577B IL258577A IL25857718A IL258577B IL 258577 B IL258577 B IL 258577B IL 258577 A IL258577 A IL 258577A IL 25857718 A IL25857718 A IL 25857718A IL 258577 B IL258577 B IL 258577B
- Authority
- IL
- Israel
- Prior art keywords
- nicotinamides
- dihydroxy
- apj agonists
- apj
- agonists
- Prior art date
Links
- XUGMSMOGPBQWJC-UHFFFAOYSA-N 4-hydroxy-2-oxo-1h-pyridine-3-carboxamide Chemical class NC(=O)C1=C(O)C=CNC1=O XUGMSMOGPBQWJC-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241367P | 2015-10-14 | 2015-10-14 | |
| US201562270659P | 2015-12-22 | 2015-12-22 | |
| PCT/US2016/056769 WO2017066402A1 (en) | 2015-10-14 | 2016-10-13 | 2,4-dihydroxy-nicotinamides as apj agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL258577A IL258577A (en) | 2018-05-31 |
| IL258577B true IL258577B (en) | 2020-07-30 |
Family
ID=57178558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258577A IL258577B (en) | 2015-10-14 | 2018-04-09 | 2,4-dihydroxy-nicotinamides as apj agonists |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10392347B2 (en) |
| EP (1) | EP3362442B1 (en) |
| JP (1) | JP6837482B2 (en) |
| KR (1) | KR20180067599A (en) |
| CN (1) | CN108368087B (en) |
| AU (1) | AU2016340264B2 (en) |
| BR (1) | BR112018007395A2 (en) |
| CA (1) | CA3001974A1 (en) |
| CL (1) | CL2018000953A1 (en) |
| CO (1) | CO2018004968A2 (en) |
| EA (1) | EA034857B1 (en) |
| ES (1) | ES2774945T3 (en) |
| IL (1) | IL258577B (en) |
| MX (1) | MX2018004344A (en) |
| PE (1) | PE20181197A1 (en) |
| SG (1) | SG10201908839QA (en) |
| TW (1) | TW201720796A (en) |
| UY (1) | UY36949A (en) |
| WO (1) | WO2017066402A1 (en) |
| ZA (1) | ZA201802451B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050317T2 (en) | 2015-05-20 | 2020-11-30 | Amgen Inc | Triazole agonists of the apj receptor |
| ES2739526T3 (en) | 2015-06-03 | 2020-01-31 | Bristol Myers Squibb Co | 4-hydroxy-3- (heteroaryl) pyridin-2-one APJ agonists for use in the treatment of cardiovascular disorders |
| US11390616B2 (en) | 2015-12-04 | 2022-07-19 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| JP6948322B2 (en) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Heteroarylhydroxypyrimidinone as an APJ agonist of APJ receptor |
| EP3433247B1 (en) | 2016-03-24 | 2021-09-08 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| WO2017218617A1 (en) * | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
| EP3468956B1 (en) | 2016-06-14 | 2021-03-03 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists |
| EP3526198B1 (en) * | 2016-10-14 | 2020-08-12 | Bristol-Myers Squibb Company | 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists |
| EP3541805B1 (en) | 2016-11-16 | 2020-10-14 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| MA46824A (en) | 2016-11-16 | 2019-09-25 | Amgen Inc | ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS APJ RECEPTOR AGONISTS |
| US10736883B2 (en) | 2016-11-16 | 2020-08-11 | Amgen Inc. | Triazole furan compounds as agonists of the APJ receptor |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| EP3704122B1 (en) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH602664A5 (en) | 1973-06-14 | 1978-07-31 | Sandoz Ag | 2-Tert. amino-alkylamino-pyrimidine derivs. |
| ZA835878B (en) * | 1982-08-23 | 1985-03-27 | Warner Lambert Co | Cardiotonic agents |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| DE4425616A1 (en) * | 1994-07-20 | 1996-01-25 | Basf Ag | Hydroxypyridonecarboxamides, their preparation and use |
| CZ298812B6 (en) | 1996-07-01 | 2008-02-13 | Dr. Reddy's Laboratories Limited | Azolidinedione derivatives, process of their preparation, pharmaceutical compositions in which the derivatives are comprised and their use in the treatment of diabetes mellitus and related diseases |
| US6943173B2 (en) | 2000-07-18 | 2005-09-13 | Neurogen Corporation | 5-substituted 2-aryl-4-pyrimidinones |
| TW200300349A (en) | 2001-11-19 | 2003-06-01 | Sankyo Co | A 4-oxoqinoline derivative |
| CA2485148A1 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
| CA2483627A1 (en) | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2004339159A (en) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | Medicinal composition containing 4-oxoquinoline derivative |
| US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP1682534A2 (en) | 2003-11-03 | 2006-07-26 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions, and methods |
| US7625912B2 (en) | 2003-12-19 | 2009-12-01 | Merck & Co. Inc | Mitotic kinesin inhibitors |
| US7732613B2 (en) | 2005-09-14 | 2010-06-08 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007037543A1 (en) | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | Biarylamide derivative |
| WO2007064797A2 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| EP2016056A4 (en) | 2006-04-21 | 2010-11-10 | Univ Boston | Ionic viscoelastics and viscoelastic salts |
| JP2007308441A (en) * | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | Heterocycle-containing compound and its application |
| WO2008052861A2 (en) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Method for producing 1,3-heteroaromatic carbonates |
| PL2079707T3 (en) | 2006-10-10 | 2015-05-29 | Proionic Gmbh | Method for reacting 1,3-heteroaromatic 2-carboxylates with water |
| CL2008000065A1 (en) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA. |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| EP3042660A3 (en) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| US20110253929A1 (en) | 2008-12-22 | 2011-10-20 | Basf Se | Mixtures of hydrophobic and hydrophilic ionic liquids and use thereof in liquid ring compressors |
| AR076601A1 (en) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | PYRIMIDINS AS THERAPEUTIC AGENTS |
| JP6075621B2 (en) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | Novel heterocyclic derivatives and pharmaceutical compositions containing them |
| KR20140039242A (en) | 2011-05-31 | 2014-04-01 | 메르크 파텐트 게엠베하 | Electrolyte formulations |
| SG195086A1 (en) | 2011-05-31 | 2013-12-30 | Merck Patent Gmbh | Compounds containing hydrido-tricyano-borate anions |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014004676A1 (en) | 2012-06-26 | 2014-01-03 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors as neuroprotective agents in the cns |
| PL2897939T3 (en) * | 2012-09-21 | 2017-08-31 | Sanofi | Benzoimidazole-carboxylic acid amide derivatives for treating metabolic or cardiovascular diseases |
| DE102012021452A1 (en) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salts with trihydroperfluoroalkoxybutanesulfonate or trihydroperfluoroalkoxypropanesulfonate anion |
| EP2970124B1 (en) | 2013-03-14 | 2019-05-22 | The Board of Trustees of the Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| WO2014207100A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | A process for coating paper with cellulose using a solution containing cellulose |
| DK3013813T3 (en) | 2013-06-27 | 2019-06-03 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands |
| ES2906062T3 (en) | 2013-11-29 | 2022-04-13 | Proionic Gmbh | Procedure for joining a thermoplastic material by means of microwave radiation |
| US10570128B2 (en) | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
| WO2015188073A1 (en) | 2014-06-06 | 2015-12-10 | Research Triangle Institute | Apelin receptor (apj) agonists and uses thereof |
| WO2016074757A1 (en) | 2014-11-11 | 2016-05-19 | Merck Patent Gmbh | Method for the preparation of mono- and bis(perfluoroalkyl)fluorophosphate salts and their acids |
| EP3957627B1 (en) | 2015-04-24 | 2024-06-19 | Shionogi & Co., Ltd | 6-membered heterocyclic derivative and pharmaceutical composition comprising same |
| HUE050317T2 (en) | 2015-05-20 | 2020-11-30 | Amgen Inc | Triazole agonists of the apj receptor |
| ES2739526T3 (en) | 2015-06-03 | 2020-01-31 | Bristol Myers Squibb Co | 4-hydroxy-3- (heteroaryl) pyridin-2-one APJ agonists for use in the treatment of cardiovascular disorders |
| KR101711744B1 (en) | 2015-07-16 | 2017-03-02 | 경희대학교 산학협력단 | Oxadiazole derivatives, preparation method thereof and electron tranport layer having the same |
| US10626096B2 (en) | 2015-11-24 | 2020-04-21 | Sanford Burnham Prebys Medical Discovery Institute | Azole derivatives as apelin receptor agonist |
| US11390616B2 (en) | 2015-12-04 | 2022-07-19 | Bristol-Myers Squibb Company | Apelin receptor agonists and methods of use |
| JP6948322B2 (en) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Heteroarylhydroxypyrimidinone as an APJ agonist of APJ receptor |
| EP3433247B1 (en) | 2016-03-24 | 2021-09-08 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
| EP3468956B1 (en) | 2016-06-14 | 2021-03-03 | Bristol-Myers Squibb Company | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists |
| WO2017218617A1 (en) | 2016-06-14 | 2017-12-21 | Bristol-Myers Squibb Company | 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists |
| EP3526198B1 (en) | 2016-10-14 | 2020-08-12 | Bristol-Myers Squibb Company | 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists |
-
2016
- 2016-10-13 CN CN201680072835.5A patent/CN108368087B/en active Active
- 2016-10-13 SG SG10201908839Q patent/SG10201908839QA/en unknown
- 2016-10-13 EP EP16784732.6A patent/EP3362442B1/en active Active
- 2016-10-13 AU AU2016340264A patent/AU2016340264B2/en not_active Ceased
- 2016-10-13 CA CA3001974A patent/CA3001974A1/en not_active Abandoned
- 2016-10-13 US US15/767,364 patent/US10392347B2/en active Active
- 2016-10-13 ES ES16784732T patent/ES2774945T3/en active Active
- 2016-10-13 KR KR1020187013119A patent/KR20180067599A/en active IP Right Grant
- 2016-10-13 EA EA201890858A patent/EA034857B1/en not_active IP Right Cessation
- 2016-10-13 PE PE2018000536A patent/PE20181197A1/en unknown
- 2016-10-13 BR BR112018007395A patent/BR112018007395A2/en not_active IP Right Cessation
- 2016-10-13 JP JP2018519425A patent/JP6837482B2/en active Active
- 2016-10-13 WO PCT/US2016/056769 patent/WO2017066402A1/en active Application Filing
- 2016-10-13 MX MX2018004344A patent/MX2018004344A/en active IP Right Grant
- 2016-10-13 UY UY0001036949A patent/UY36949A/en unknown
- 2016-10-13 TW TW105133123A patent/TW201720796A/en unknown
-
2018
- 2018-04-09 IL IL258577A patent/IL258577B/en active IP Right Grant
- 2018-04-13 ZA ZA2018/02451A patent/ZA201802451B/en unknown
- 2018-04-13 CL CL2018000953A patent/CL2018000953A1/en unknown
- 2018-05-10 CO CONC2018/0004968A patent/CO2018004968A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3001974A1 (en) | 2017-04-20 |
| ES2774945T3 (en) | 2020-07-23 |
| CN108368087B (en) | 2022-04-12 |
| BR112018007395A2 (en) | 2018-10-23 |
| ZA201802451B (en) | 2020-01-29 |
| WO2017066402A1 (en) | 2017-04-20 |
| US20180297954A1 (en) | 2018-10-18 |
| CN108368087A (en) | 2018-08-03 |
| JP2018530591A (en) | 2018-10-18 |
| TW201720796A (en) | 2017-06-16 |
| AU2016340264B2 (en) | 2021-01-07 |
| PE20181197A1 (en) | 2018-07-23 |
| EA034857B1 (en) | 2020-03-30 |
| IL258577A (en) | 2018-05-31 |
| EA201890858A1 (en) | 2018-09-28 |
| UY36949A (en) | 2017-04-28 |
| US10392347B2 (en) | 2019-08-27 |
| MX2018004344A (en) | 2018-05-01 |
| SG10201908839QA (en) | 2019-10-30 |
| CO2018004968A2 (en) | 2018-10-10 |
| EP3362442B1 (en) | 2020-01-29 |
| KR20180067599A (en) | 2018-06-20 |
| AU2016340264A1 (en) | 2018-05-31 |
| JP6837482B2 (en) | 2021-03-03 |
| EP3362442A1 (en) | 2018-08-22 |
| CL2018000953A1 (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802451B (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| IL288232A (en) | 1,7-naphthyridines as immunomodulators | |
| ZA201806356B (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| ZA201807350B (en) | Novel compounds as gpr119 agonists | |
| HK1255163A1 (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| GB201507594D0 (en) | Intamac 1 | |
| HRP20190107T1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| IL247773A0 (en) | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | |
| SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| HK1254800A1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| GB201519732D0 (en) | Mrbr.2 | |
| AU5457P (en) | JOAe 6656 Aeonium arborium | |
| GB201521485D0 (en) | . | |
| GB201500297D0 (en) | Agonists | |
| GB201518402D0 (en) | Products, uses & methods (8) | |
| GB201510891D0 (en) | Products, uses & methods (7) | |
| GB201509366D0 (en) | Products, uses & methods (6) | |
| GB201507774D0 (en) | Products, uses & methods (2) | |
| GB201507776D0 (en) | Products, uses & methods (4) | |
| GB201507775D0 (en) | Products, uses & methods (3) | |
| GB201507773D0 (en) | Products, uses & methods (1) | |
| GB201513785D0 (en) | Aerocar 1 | |
| GB201513303D0 (en) | Kapiche 1 | |
| GB201509410D0 (en) | Tidysqueeze 4 | |
| GB201503680D0 (en) | Whatyouwearing.com |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |